Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.
An FDA advisory panel will be asked to vote on whether a diabetes drug made by Eli Lilly and Boehringer Ingelheim cuts the risk of cardiovascular death, according to the agency’s website.
Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.
AstraZeneca PLC (AZN) Coughs Up $2.7 Billion for Bay Area’s ZS Pharma (ZSPH) and its Hyperkalemia Treatment
Big Pharma, Breakthrough Therapy, Breakthrough Therapy Designation, Cardiovsacular, Chronic Kidney Disease, Clinical Trials, Deals, Deals, Diabetes, EMA, Fast Track, Fast Track Designation, FDA, FDA/Regulatory, Health, Hyperkalemia, Ion Trap, Kidney Disease, M&A, M&A, Metabolic, Orphan Diseases, Orphan Drug Designation, Orphan Drugs, PDUFA, Potential Blockbusters, R&D, Shares, Shares, TechnologyLONDON – Looking to strengthen its cardiovascular and metabolic offerings, London-based AstraZeneca (AZN) is snapping up Bay Area-based ZS Pharma (ZSPH) in a deal worth $2.7 billion in hopes of […]
U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG’s treatment, Stalevo, for Parkinson’s disease. Recommendations for using the drug, which […]
PARSIPPANY, N.J., Oct. 16, 2015 /PRNewswire/ — Daiichi Sankyo, Inc. (“the Company”) announced today that it will reorganize its U.S. Commercial organization as it begins to transition from a maturing […]
Novartis AG launched a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries, the drugmaker said in a statement on Thursday. The Basel-based company said […]
New guidelines for prescribing cholesterol-lowering medications are efficient and cost-effective, according to two new studies. The new research, published in JAMA, examines the 2013 recommendation that people ages 40 to […]